RESUMO
In Argentina, vaccines included in the national calendar are mandatory, free of charge, and access to vaccination services with social equity for all stages of life are guaranteed by law. However, vaccination coverages are still suboptimal and have shown a constant decrease in the last five years. This study aimed to perform a survey to describe the parent's confidence, risk perception, sources of information and access barriers to vaccines and vaccination in Argentina. A survey was designed for parents in charge of children under 12 years of age to answer. The questionnaire was constructed based on validated questions of the international peer-reviewed literature adapted to our country's characteristics. The survey was performed on 1,202 respondents, covering all regions of Argentina, between 19th May and 18th June 2020. To highlight, 76.6 % were female and the mean age was 40.72 (±9.36 years). 9 % participants reported to assist to the private vaccination center, while 64 % and 23 % referred to take their children to the public vaccination point (primary care center and hospital, respectively). Additionally, respondents agreed that vaccines are safe (92 %), effective (94 %), and important for children to receive them (98 %). 48 % could identify-one or more barriers to vaccination, access and affordability were the most reported ones (74 %) being the lack of vaccine the main reason. In conclusion, this study showed that the great majority of parents trust in vaccines and health care teams but access and affordability reasons emerged as the main barriers to vaccination in our country.
Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Vacinas , Criança , Humanos , Feminino , Adulto , Masculino , Argentina , Vacinação , Pais , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children aged 12 months in 2005. Between 2005 and 2011, a dramatic decline was observed in HAV infection rates, fulminant hepatitis, and liver transplantation. This study assessed current viral circulation and estimated protective antibody persistence 4 years after vaccination. METHODS: Prevalence of prevaccination anti-HAV antibodies in 12-month-old children was evaluated as an indirect estimation of viral circulation (Group A). Seroprevalence was also measured in 5-year-old children who received 1 dose of HAV vaccine at 1 year of age (Group B). Blood samples were tested for immunoglobulin (Ig)G anti-HAV antibodies (seroprotection = ≥10 mIU/mL). All Group A-positive samples were tested for IgM anti-HAV antibodies to identify recent infections. Logistic regression analysis was done to evaluate associations between demographic and socioeconomic variables and seroprotection. RESULTS: Of 433 children from Group A, 29.5% (95% confidence interval [CI], 25.2-33.8) were positive for IgG anti-HAV antibodies with a geometric mean concentration (GMC) of 6.17 mIU/mL (95% CI, 5.33-7.15 mIU/mL); all IgM anti-HAV were negative. From 1139 in Group B, 93% (95% CI, 91.7-94.6) maintained seroprotection with a GMC of 97.96 mIU/mL (95% CI, 89.21-107.57 mIU/mL). Kindergarten attendance was associated with seroprotection in Group B (odds ratio [OR], 2.0; 95% CI, 1.26-3.3). In contrast, high maternal educational level was associated with a lack of seroprotection in this group (OR, .26; 95% CI, .09-.8). CONCLUSIONS: Single-dose, universal hepatitis A immunization in infants resulted in low HAV circulation and persistent immunologic protection up to 4 years in Argentina. Variables associated with presence or absence of seroprotection in vaccinated children could be related to differences in hygiene habits in settings with residual viral circulation.
Assuntos
Anticorpos Anti-Hepatite A/sangue , Vacinas contra Hepatite A/uso terapêutico , Hepatite A/prevenção & controle , Argentina/epidemiologia , Pré-Escolar , Feminino , Hepatite A/epidemiologia , Humanos , Esquemas de Imunização , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Lactente , Masculino , Estudos SoroepidemiológicosAssuntos
Doença de Chagas/epidemiologia , Transplante de Rim , Complicações Pós-Operatórias/epidemiologia , Adulto , Soro Antilinfocitário/uso terapêutico , Argentina , Azatioprina/uso terapêutico , Cadáver , Doença de Chagas/complicações , Criança , Ciclosporina/uso terapêutico , Feminino , Seguimentos , Rejeição de Enxerto/tratamento farmacológico , Humanos , Imunossupressores/uso terapêutico , Transplante de Rim/imunologia , Doadores Vivos , Metilprednisolona/uso terapêutico , Parasitemia/epidemiologia , Prednisona/uso terapêutico , Estudos Prospectivos , Recidiva , Estudos Retrospectivos , Doadores de TecidosRESUMO
Distingue en general dos tipos de tratamiento para los efluentes de la industria conservera: primarios, que tienen como objeto la eliminación de la mayor parte de los sólidos suspendidos y flotantes; secundarios, que son los que dan los medios para satisfacer la reducción de la demanda bioquímica de oxígeno. Entre los tratamientos secundarios se mencionan los métodos químicos, físicos y biológicos. Luego detalla el trabajo realizado en aguas servidas de la industria conservera en Mendoza, Argentina, desde 1967 a 1976
Assuntos
Argentina , Efluentes Industriais , Indústria de Conservas , Tratamento Primário , Tratamento SecundárioRESUMO
Distingue en general dos tipos de tratamiento para los efluentes de la industria conservera: primarios, que tienen como objeto la eliminación de la mayor parte de los sólidos suspendidos y flotantes; secundarios, que son los que dan los medios para satisfacer la reducción de la demanda bioquímica de oxígeno. Entre los tratamientos secundarios se mencionan los métodos químicos, físicos y biológicos. Luego detalla el trabajo realizado en aguas servidas de la industria conservera en Mendoza, Argentina, desde 1967 a 1976